Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Camp4 Therapeutics (CAMP) over the last 1 years, with Sep 2025 value amounting to $75.3 million.

  • Camp4 Therapeutics' Cash & Equivalents rose 2878.64% to $75.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year increase of 2878.64%. This contributed to the annual value of $64.0 million for FY2024, which is 66.86% up from last year.
  • Per Camp4 Therapeutics' latest filing, its Cash & Equivalents stood at $75.3 million for Q3 2025, which was up 92.58% from $39.1 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' Cash & Equivalents ranged from a high of $75.3 million in Q3 2025 and a low of $2.5 million during Q3 2024.
  • In the last 3 years, Camp4 Therapeutics' Cash & Equivalents had a median value of $49.3 million in 2025 and averaged $45.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 94.99% in 2024, then surged by 2,878.64% in 2025.
  • Quarterly analysis of 3 years shows Camp4 Therapeutics' Cash & Equivalents stood at $38.4 million in 2023, then surged by 66.86% to $64.0 million in 2024, then surged by 2,878.64% to $75.3 million in 2025.
  • Its Cash & Equivalents stands at $75.3 million for Q3 2025, versus $39.1 million for Q2 2025 and $49.3 million for Q1 2025.